Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
10
2019
accepted:
16
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
9
10
2020
Statut:
epublish
Résumé
Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib for patients with IPF and forced vital capacity (FVC) ≤ 50%. This was a multi-center retrospective study performed by the Okayama Respiratory Disease Study Group. Patients were allocated into FVC ≤ 50% and FVC > 50% groups based on their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12 months. 45 patients were eligible for the study. 18 patients had FVC ≤ 50%, and 27 patients had FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12 months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12 months after initiating nintedanib were comparable between the two groups. Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with changes in FVC at 6 months after initiating nintedanib. Our data suggest that nintedanib can be a useful agent for IPF patients, including those with a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following nintedanib treatment.
Sections du résumé
BACKGROUND
Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib for patients with IPF and forced vital capacity (FVC) ≤ 50%.
METHODS
This was a multi-center retrospective study performed by the Okayama Respiratory Disease Study Group. Patients were allocated into FVC ≤ 50% and FVC > 50% groups based on their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12 months.
RESULTS
45 patients were eligible for the study. 18 patients had FVC ≤ 50%, and 27 patients had FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12 months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12 months after initiating nintedanib were comparable between the two groups. Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with changes in FVC at 6 months after initiating nintedanib.
CONCLUSIONS
Our data suggest that nintedanib can be a useful agent for IPF patients, including those with a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following nintedanib treatment.
Identifiants
pubmed: 32853277
doi: 10.1371/journal.pone.0236935
pii: PONE-D-19-28976
pmc: PMC7451511
doi:
Substances chimiques
Indoles
0
nintedanib
G6HRD2P839
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236935Déclaration de conflit d'intérêts
Takuo Shibayama has received research funding from Nippon Boeringer Ingerheim Co., Ltd. Kanehiro Arihiko has received honoria from Nippon Boeringer Ingerheim Co., Ltd. Katsuyuki Kiura has received research funding and donation from Nippon Boeringer Ingerheim Co., Ltd. The other authors have nothing to declare.
Références
Drug Des Devel Ther. 2018 Oct 09;12:3369-3375
pubmed: 30349191
Respiration. 2018;95(6):433-440
pubmed: 29587263
Am J Respir Crit Care Med. 2001 Oct 1;164(7):1171-81
pubmed: 11673205
Lung. 2016 Oct;194(5):739-43
pubmed: 27377558
Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):450-4
pubmed: 8306044
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1605; author reply 1605-6
pubmed: 16339012
Eur Respir J. 2018 Aug 2;52(2):
pubmed: 29946007
Respir Investig. 2015 Jan;53(1):7-12
pubmed: 25542598
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
Respir Res. 2018 Oct 19;19(1):203
pubmed: 30340638
Am J Respir Crit Care Med. 2014 Oct 1;190(7):773-9
pubmed: 25162152
Chron Respir Dis. 2016 Feb;13(1):40-7
pubmed: 26374300
Respir Investig. 2018 Jul;56(4):268-291
pubmed: 29980444
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066